tbuckley/cabot-search huggingface dataset:
AB0920 THE EFFECT OF TIBIALIS POSTERIOR MUSCLE FATIQUE PROTOCOL ON THE STATIC AND DYNAMIC FOOT PARAMETERS
Authors: Azize Reda Tunç, Yasin Tunç, Nilgün Bek
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> The tibialis posterior has a important key role as an invertor of the rearfoot. Also providing dynamic support across the midfoot. The value of the tibialis posterior shown by biomechanical research conducted on patients with posterior tibialis tendon dysfunction. One method of assessing a muscle's contribution to a specific movement pattern is via fatigue-inducing exercise of that muscle. Consequently, to realize the role of tibialis posterior fatigue on foot mechanics it seems prudent to use an exercise that more selectively activates this muscle (1,2). <h3>Objectives</h3> The purpose of this study is to investigate dynamic and static foot parametres changed by tibialis posterior muscle fatique protocol. <h3>Methods</h3> Thirty patients were participated in this study. Socio-dermographic and descriptive characteristics of the participants were recorded. The changes on the dynamic and static parametres of foot were measured by pedobarography. The two exercises selected for the fatigue protocol are: 1-Unilateral heel raise 2-Close chain resisted foot adduction. Fatigue level was measured by Borg scale. Static and dynamic parameters obtained before and after fatigue protocol were compared. <h3>Results</h3> The mean age of the patients was 24,88 ± 4,39 years, mean height was 171 ± 7,89 cm and mean weight was 68,7 ± 14,5 kg. We found significiant increase in the maximum pressure measurement of mid foot (p= 0,004). In the total contact area during the static position, there were no significant changes (p&gt;0.05). Participants' maximal pressure in the middle standing phase was changed from 19,78 ± 10,71 N/cm<sup>2</sup> to 22.89 ± 13.03 N/cm2 after fatigue protocol in medial of middle foot (p=0.03). <h3>Conclusion</h3> According to the results, there was a correlation between the fatique of tibialis posterior and the static and dynamic parameters of foot. The increase in the middle foot peak pressure distributions after the fatigue protocol of the tibialis posterior muscle can be explained as the increase of the angular amount of pronation and prolongation of the time with the middle standing phase. Increase in pressure forces of the middle foot and increase in percentages of the area cause increase of the weight in the front foot during the gait cycle. Thus, fatigue protocol causes similar effects as tibialis posterior muscle dysfunction. <h3>References</h3> [1] Bubra, P. S., Keighley, G., Rateesh, S., &amp; Carmody, D. (2015). Posterior tibial tendon dysfunction: an overlooked cause of foot deformity. Journal of family medicine and primary care, 4(1), 26. [2] Pohl, M. B., Rabbito, M., &amp; Ferber, R. (2010). The role of tibialis posterior fatigue on foot kinematics during walking. Journal of foot and ankle research, 3(1), 6. <h3>Disclosure of Interests</h3> None declared
MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial
Authors: Sepideh Saadatmand, H Amarens Geuzinge, Emiel J T Rutgers, Ritse M Mann, Diderick B W de Roy van Zuidewijn, Harmien M Zonderland, Rob A E M Tollenaar, Marc B I Lobbes, Margreet G E M Ausems, Martijne van 't Riet, Maartje J Hooning, Ingeborg Mares-Engelberts, Ernest J T Luiten, Eveline A M Heijnsdijk, Cees Verhoef, Nico Karssemeijer, Jan C Oosterwijk, Inge-Marie Obdeijn, Harry J de Koning, Madeleine M A Tilanus-Linthorst, Carolien HM van Deurzen, Claudette E Loo, Jelle Wesseling, Margrethe Schlooz-Vries, Suzan van der Meij, Wilma Mesker, Kristien Keymeulen, Carolien Contant, Eva Madsen, Linetta B Koppert, Joost Rothbarth, Wouter B Veldhuis, Arjen J Witkamp, Eric Tetteroo, Cecile de Monye, Mandy M van Rosmalen, Jolanda Remmelzwaal, Huub B W Gort, Roelie Roi-Antonides, Martin NJM Wasser, Edith van Druten
Journal: The Lancet Oncology (2019)
Abstract 19716: Recommended Use of the Pooled Cohort Equations Over-Estimates Cardiovascular Risk in Hispanics: Evidence from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) and the Multi-Ethnic Study of Atherosclerosis (MESA)
Authors: Kenny Shum, Pengfei Zheng, Tuan Dinh, Corinne V Evans, Wiley Chan, Evelyn P Whitlock
Journal: Circulation (2014)

Introduction: The ACC/AHA Pooled Cohort Equations for estimating 10-year atherosclerotic cardiovascular disease (ASCVD) were derived from cohorts of Whites and African Americans, with no representa...
The gut microbiota regulates white adipose tissue inflammation and obesity via a family of microRNAs
Authors: Anthony T. Virtue, Sam J. McCright, Jasmine M. Wright, Monica T. Jimenez, Walter K. Mowel, Jonathan J. Kotzin, Leonel Joannas, Megha G. Basavappa, Sean P. Spencer, Megan L. Clark, Stephen H. Eisennagel, Adam Williams, Maayan Levy, Sasikanth Manne, Sarah E. Henrickson, E. John Wherry, Christoph A. Thaiss, Eran Elinav, Jorge Henao-Mejia
Journal: Science Translational Medicine (2019)

The gut microbiota is a key environmental determinant of mammalian metabolism. Regulation of white adipose tissue (WAT) by the gut microbiota is a process critical to maintaining metabolic fitness, and gut dysbiosis can contribute to the development of obesity and insulin resistance (IR). However, how the gut microbiota regulates WAT function remains largely unknown. Here, we show that tryptophan-derived metabolites produced by the gut microbiota controlled the expression of the miR-181 family in white adipocytes in mice to regulate energy expenditure and insulin sensitivity. Moreover, dysregulation of the gut microbiota-miR-181 axis was required for the development of obesity, IR, and WAT inflammation in mice. Our results indicate that regulation of miR-181 in WAT by gut microbiota-derived metabolites is a central mechanism by which host metabolism is tuned in response to dietary and environmental changes. As we also found that MIR-181 expression in WAT and the plasma abundance of tryptophan-derived metabolites were dysregulated in a cohort of obese human children, the MIR-181 family may represent a potential therapeutic target to modulate WAT function in the context of obesity.
AB0495 INCREASED WORK LOSS DURING PREGNANCY IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS COMPARED TO MATCHED HEALTHY CONTROLS
Authors: Birgit Blomjous, Marieke Ter Wee, Alexandre Voskuyl, Hanneke de Vries, Irene E.M. Bultink
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Women with systemic lupus erythematosus (SLE) might be more vulnerable to reduce or stop working during pregnancy because of the increased risk of pregnancy complications compared to the general population. However, no data on work loss during pregnancy and return to work after maternity leave in patients with SLE are available. <h3>Objectives</h3> We aimed to investigate several work outcomes during and after pregnancy in women with SLE compared to matched pregnant controls. <h3>Methods</h3> A case-control study on employment was performed in pregnant women with SLE and matched controls. Matching criteria were age, year of delivery, and number of living infants. Employment was defined as having ≥8 hours/week of paid work before conception. Four work outcomes were investigated: interruption of work for &gt;1 week during pregnancy, complete cessation of work for &gt;1 week until delivery, reduction in working hours during pregnancy, and the time in weeks to return to work after maternity leave. <h3>Results</h3> A total of 42 women were included (21 SLE patients, 21 controls). Mean SELENA-SLEDAI before pregnancy in SLE patients was 2.6 (SD 2.3). Interruption of work for &gt;1 week or completely stop working during pregnancy occurred in 10 SLE women, compared to 2 controls (OR=8.6, 95% CI [1.6-46.8], p=0.012). From the women who completely stopped working until delivery (n=8), 7 women had SLE (OR=1.4, 95% CI [0.07-28.1], p=0.826). In addition, in women continuing work, reduction of working hours occurred in 5 women with SLE versus 3 controls (OR=1.9, 95% CI [0.4-9.1], p=0.436). After delivery, the median (IQR) duration of return to work after maternity leave was 4 weeks after maternity leave (0 - 6.8) for women with SLE and 2 weeks later (0 - 4) for controls (Mann-Whitney U test; p=0.977). No difference in number of women with delay of return to work after maternity leave (yes/no) was found between women with SLE and controls (n=9 versus n=11, respectively; OR=1.0, 95% CI [0.3-3.7], p=0.973). <h3>Conclusion</h3> Pregnant women with SLE more frequently completely stop working or reduce working hours compared to matched healthy controls. These findings warrant improved counseling of these women and attention of health care providers, including company doctors. <h3>Disclosure of Interests</h3> Birgit Blomjous Speakers bureau: UCB Pharma BV, Marieke ter Wee Grant/research support from: Nonrestricted grant from Lilly Netherlands BV, Speakers bureau: ARC Preceptorship program, Alexandre Voskuyl: None declared, Hanneke de Vries Grant/research support from: Pfizer, Speakers bureau: UCB Pharma BV, Irene E.M. Bultink Consultant for: Consultant fee from Sanofi Genzyme, Speakers bureau: Speaker fees from Lilly Netherlands BV, MSD Corp, Amgen BV, UCB Pharma BV, Roche Netherlands BV and Sanofi Genzyme
Target selection for CAR-T therapy
Authors: Jianshu Wei, Xiao Han, Jian Bo, Weidong Han
Journal: Journal of Hematology & Oncology (2019)

Chimeric antigen receptor-modified T (CAR-T) cells have achieved significant success in the treatment of several hematological malignancies. However, the translation of the existing achievements into the treatment of other tumors, especially solid tumors, is not smooth. In addition to the optimization of CAR structures, preparation, and clinical protocols, rational selecting and utilizing the targets was more pivotal. In this review, the criteria for target selection and some new strategies for targets utilization were summarized and discussed. This systematic review will help researchers better understand how the efficacy and safety of CAR-T treatment would be affected by targets and thus more rationally select targets and conduct clinical trials.
Abstract 17259: Impact of Older Age (>80 Years) and Gender on Long-Term Outcomes in Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention
Authors: Hisanori Yui, Kyuhachi Otagiri, Takashi Miura, Naoyuki Abe, Yuzo Hisatsugu, Daisuke Kashiwagi, Keisuke Machida, Takahiro Tachibana, Takashi Yanagisawa, Naoto Hashizume, Takahiro Kobayashi, Tamon Katoh, Kenichi Karube, Masafumi Kanai, Chie Nakamura, Takahiro Sakai, Takahiro Takeuchi, Hiroshi Kitabayashi
Journal: Circulation (2017)

Background: Older age has been proved to be an important risk factor for coronary artery disease (CAD). Previous studies have reported that women undergoing percutaneous coronary intervention (PCI)...
Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment
Authors: Tong-Fei Li, Ke Li, Chao Wang, Xin Liu, Yu Wen, Yong-Hong Xu, Quan Zhang, Qiu-Ya Zhao, Ming Shao, Yan-Ze Li, Min Han, Naoki Komatsu, Li Zhao, Xiao Chen
Journal: Journal of Controlled Release (2017)
Whole-Genome Genomics Correlates of Response to Anti-PD1 Therapy in Relapsed/Refractory Natural Killer/T Cell Lymphoma
Authors: Jing Quan Lim, Tiffany Tang, Daryl Tan, Yurike Laurensia, Burton Chia Kuan Hui, Jabed Iqbal, Dachuan Huang, Tammy Song, Cedric Chuan Young Ng, Huangming Hong, Rex Au-Yeung, Benjamin Mow, Qichun Cai, LM Poon, Yok-Lam Kwong, Jin-Xin BEI, Tongyu Lin, Soon Thye Lim, Choon Kiat Ong
Journal: Blood (2018)
FRI0311 PREVALENCE AND CLINICAL MANIFESTATIONS OF ERASMUS SYNDROME IN SYSTEMIC SCLEROSIS: A CROSS-SECTIONAL STUDY
Authors: Soraia Azevedo, Joana Neves, Daniela Faria, Joana Silva, Joana Rodrigues, Daniela Peixoto, José Tavares-Costa, Sérgio Alcino, Carmo Afonso, Filipa Teixeira
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Erasmus syndrome (ErS) is defined by the association of exposure to silica with the subsequent development of systemic sclerosis (SSc), with or without associated silicosis. <h3>Objectives</h3> The objectives of this study were, on one hand, to evaluate the prevalence of ErS in a population of SSc patients and to characterize the cases and, on the other hand, to evaluate the clinical and laboratory characteristics of SSc patients with or without exposure to silica. <h3>Methods</h3> We performed a cross-sectional study of the patients with SSc in our department. Demographics, clinical and laboratory data were collected from all patients with SSc diagnosed according to ACR/EULAR criteria. Moreover, a telephone call was made in order to detail the professional activity and possible exposure to silica. <h3>Results</h3> The prevalence of ErS in this population was 15.3% (9/59). All cases identified were male, corresponding to 75% of men with SSc followed at our department. There was a statistically significant association between ErS and male gender (p&lt;0.001), initial pulmonary manifestation (p=0.025), history of digital ulcers (p=0.014) and smoking (p=0.047). On the other hand, a lower risk of gastrointestinal involvement was found in ErS cases (p=0.008). All patients with ErS had positive autoantibodies (mainly anti-Scl70 and anti-centromere) with titters tending to be higher than SSc without ErS, although without statistically significant differences. In addition, although with no statistical significance, we found that pulmonary artery systolic pressure (PASP) estimated by echocardiogram was higher in patients with ErS. <h3>Conclusion</h3> In our study, prevalence of ErS was higher than data from previously published literature. For a more accurate ErS diagnosis it is necessary to be aware of and investigate less intense silica exposures, which may have occurred many years before diagnosis. Statistically significant differences were found between ErS and SSc without exposure to silica; this fact may have impact in diagnosis, treatment and prognosis. <h3>References</h3> [1] Erasmus L.D. et al. [2] Pollard K. M. et al. [3] West S. G.et al. [4] Elhai M et al. [5] Ferri C etal [6] Mora G. F. et al. [7] Haustein UH et al. [8] Rosenman KD et al. [9] Van Loveren H et al. [10] Rocha L.F. et al. [11] Sharma RK et al. [12] Rustin M. H. et al. [13] Marie I et al. [14] Magnant J et al. [15] Van den Hoogen F et al. [16] Sebastiani M et al. [17] Leroy EC et al. [18] Marie I, et al. [19] Elhai M et al. [20] Makol A. et al. [21] Rodnan G.P. et al. [22] Subrata Chakrabarti et al. [23] Bello S et al. [24] Burns C.J. et al. [25] Galluccio F et al. [26] Forbes A et al. [27] MacHugh NJ et al. [28] Czirjak L et al. <h3>Disclosure of Interests</h3> None declared
Abstract 17163: Clinical Outcome of Asymptomatic Patients With Very Severe Aortic Stenosis on Conservative Strategy
Authors: Koichiro Murata, Tomohiko Taniguchi, Takeshi Morimoto, Tomoya Onodera, Takeshi Kimura
Journal: Circulation (2017)

Introduction: Current guidelines have recommended a watchful waiting strategy for asymptomatic patients with severe aortic stenosis (AS), however aortic valve replacement (AVR) is sometimes indicat...
FRI0063 EFFECTS OF MALALIGNMENT AND DISEASE ACTIVITY ON SECONDARY OSTEOARTHRITIS PROGRESSION IN KNEES OF RHEUMATOID ARTHRITIS PATIENTS
Authors: Noriaki Okumura, Taku Kawasaki, Kosuke Kumagai, Mitsuhiko Kubo, Takafumi Yayama, Tomohiro Mimura, Tsutomu Maeda, Shinji Imai
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Recent advancements in treatment of rheumatoid arthritis (RA) with disease-modifying anti-rheumatic drugs (DMARDs) have been remarkable, with disease symptoms nearly disappearing due to their strong anti-inflammatory action and many patients achieving remission. As a result, the need for RA-related surgery has shown a yearly decreasing trend, especially knee surgery and synovectomy procedures [1]. On the other hand, cases of secondary osteoarthritis (OA) in knee joints as a symptom associated with RA following a total knee arthroplasty (TKA) are increasing. <h3>Objectives:</h3> We investigated the morphology of osteophytes by quantitatively evaluating their size using images obtained prior to performing a TKA. Additionally, the relationships of osteophyte size with patient background, disease activity, and degree of inflammation were examined. <h3>Methods:</h3> Radiographs of 35 consecutive knees in 30 RA patients (26 females, 4 males; mean age 63.0 years; median disease duration 15 years) who underwent TKA, including preoperative standing AP view radiographs of the knee joint, were retrospectively analyzed. Using the Image-J software package, osteophyte size in the medial femur (MF), medial tibia (MT), lateral femur (LF), and lateral tibia (LT) regions was determined. Written informed consent for data collection was obtained from all patients in accordance with the Declaration of Helsinki. <h3>Results:</h3> Preoperative Larsen grade was 2, 3, 4, and 5 in 1, 12, 18, and 2 patients, respectively, while the mean range of motion of the knee joint was 118° for flexion and -10° for extension. The mean femorotibial angle (FTA) was 178±13.6°, with varus (FTA &gt;180°, n=14) more frequently observed as compared to valgus (FTA &lt;170°, n=7) cases. Mean osteophyte size in the MF, MT, LF, and LT regions was 37.2, 17.0, 27.2, and 4.57 mm<sup>2</sup>, respectively, and significantly greater in the medial compartment (MF+MT) than the lateral compartment (LF+LT) (p&lt;0.001). In the varus cases, osteophyte size in the medial compartment was significantly larger as compared to the normal and valgus cases (p=0.0016). Furthermore, osteophyte size in the medial compartment was negatively correlated with the inflammatory markers CRP (r=-0.492, p=0.0027) and ESR (r=-0.529, p=0.0016), whereas that in the lateral compartment was negatively correlated with disease activity (r=-0.589, p=0.0023). <h3>Conclusion:</h3> Our results suggest that secondary OA is a more prominent symptom in RA patients in whom inflammation is controlled, while disease activity has effects on osteophyte size. <h3>Reference:</h3> [1] Momohara S, Ikari K, Mochizuki T, et al: Declining use of synovectomy surgery for patients with rheumatoid arthritis in Japan. Ann Rheum Dis 2009;68:291-2. <h3>Disclosure of Interests:</h3> None declared
Abstract 13823: The Cut-off Point and Boundary Values of Waist-to-height Ratio as an Indicator for Cardiovascular Risk Factors in Chinese Adults Population From PURE Study
Authors: Yaguang Peng, Wei Li
Journal: Circulation (2015)

Objectives: To explore a scientific boundary of WHtR to evaluate central obesity and CVD risk factors in Chinese adult population. Methods: The data from the Prospective Urban Rural Epidemiology (PURE) China study that carried out during 2005-2007. The final study analytical sample consisted of 43 841 participants (18 019 men and 25 822 women) aged 35-70 years. According to the category of CVD risk factors proposed by Joint National Committee 7 version (JNC7) and the clustering of risk factors, some diagnosis parameters, such as sensitivity, specificity, and receiver operating characteristic (ROC) curve least distance were calculated for hypertension, diabetes, high serum triglyceride (TG), high serum low density lipoprotein cholesterol (LDL-C), low serum high density lipoprotein cholesterol (HDL-C) and clustering of risk factors (number≥2) to evaluate the efficacy each value of WHtR cut-off point. The upper boundary value for severity was fixed on the point whose specificity of the point was gathered more than 90%. And the lower boundary value to indicate over low weight was determined by the percentile distribution of WHtR, at which the 5 th percentile (P 5 ) of point, both in male and female population. Then, basis on the principle of convenient and practical for use, determine the optimal boundary values of WHtR for low weight and obvious central obesity. Results: For the whole study population, the optimal WHtR cut point for CVD risk factors cluster was 0.50.The cut points for severe central obesity were 0.57 in the whole population. The upper boundary values of WHtR to detect risk factors cluster with specificity above 90% were 0.55 and 0.58 for men and women, respectively. Additionally, the cut-off points of WHtR for each of 4 cardiovascular risk factors with specificity above 90% in male ranged from 0.55 to 0.56, while in female ranged from 0.57 to 0.58. The P 5 of WHtR, which the lower boundary values of WHtR to indicate over low weight, was 0.40 in the whole population. Conclusion: WHtR 0.50 was an optimal cut point for CVD risks evaluation in Chinese adults population for both genders. The optimal boundaries of WHtR were 0.40 and 0.57 indicating low body weight and severe risk for CVD respectively in Chinese adults.
PF403 NEGATIVE MR4.0 CHRONIC MYELOID LEUKEMIA AND ITS IMPLICATIONS FOR TREATMENT‐FREE REMISSION
Authors: N. Cerveira, J. Diamond, S. Matos, M.L. Amorim, M. Coucelo, S. Bizarro, A.T. Simões, F. Pierdomenico, M. Lopes, L. Ribeiro, M. Carmo‐Fonseca, J.E. Guimarães, A. Almeida, M.R. Teixeira
Journal: HemaSphere (2019)

Background: In the last few years, several clinical discontinuation trials have demonstrated that 40–60% of chronic phase CML patients (CP‐CML) who have achieved a stable deep molecular response, can stop therapy without relapsing. However, there is no consensus as to whether or not the depth of the molecular response is a prognostic factor for treatment‐free remission (TFR), which is reflected in the discrepancy between the various guidelines and opinions of experts in the field regarding the optimal molecular response required, MR 4.0 or MR 4.5 , for a TFR attempt. Aims: In this work, we hypothesize that a discrepancy in the classification of the level of molecular response between laboratories involved in clinical trials could introduce a bias in the evaluation of the prognostic impact of treatment‐free remission (TFR). Methods: In an attempt to clarify this issue, we stratified by molecular response a cohort of 1087 CML patients and compared our results with those of 200 patients enrolled in the EURO‐SKI trial. Results: We found that none of the patients classified as MR 4.0 had detectable disease (0/169) (Figure 1A). In addition, the frequency of undetectable disease negative cases increased to 29% (61/211) and 65% (149/230) in the MR 4.5 and MR 5.0 groups, respectively (Figure 1A). By contrast, the frequency of MR 4.0 with undetectable disease in the EURO‐SKI trial was 72% (49/68), decreasing to 56% (48/85) and 58% (25/43) in the MR 4.5 and MR 5.0 groups, respectively (Figure 1B). Summary/Conclusion: Our results suggest that (1) There may be a bias in patient stratification by molecular response in the EURO‐SKI trial, making it impractical to attempt any association between molecular response depth and TFR success, (2) we should reassess the current classification of MR 4.0 to include only patients with detectable disease and (3) the minimum quality criteria for scoring molecular response when disease is undetectable should be raised, with samples with &lt;32000 ABL1 or &lt;77000 GUSB transcripts be considered as unevaluable for classification of DMR. image